EP1351584A2 - Nutritional composition for a bone condition - Google Patents
Nutritional composition for a bone conditionInfo
- Publication number
- EP1351584A2 EP1351584A2 EP02702265A EP02702265A EP1351584A2 EP 1351584 A2 EP1351584 A2 EP 1351584A2 EP 02702265 A EP02702265 A EP 02702265A EP 02702265 A EP02702265 A EP 02702265A EP 1351584 A2 EP1351584 A2 EP 1351584A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition according
- vitamin
- composition
- inulin
- fos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 26
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 22
- 239000011575 calcium Substances 0.000 claims abstract description 16
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 16
- 235000001465 calcium Nutrition 0.000 claims abstract description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 15
- 230000002265 prevention Effects 0.000 claims abstract description 13
- 229920001202 Inulin Polymers 0.000 claims abstract description 12
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 12
- 229940029339 inulin Drugs 0.000 claims abstract description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 7
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 7
- 239000011777 magnesium Substances 0.000 claims abstract description 7
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 7
- 235000001055 magnesium Nutrition 0.000 claims abstract description 7
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000003687 soy isoflavones Nutrition 0.000 claims abstract description 7
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 7
- 239000011710 vitamin D Substances 0.000 claims abstract description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 7
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 7
- 239000011712 vitamin K Substances 0.000 claims abstract description 7
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 7
- 229940046008 vitamin d Drugs 0.000 claims abstract description 7
- 229940046010 vitamin k Drugs 0.000 claims abstract description 7
- 239000011701 zinc Substances 0.000 claims abstract description 7
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 7
- 235000016804 zinc Nutrition 0.000 claims abstract description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 5
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 5
- 229910052802 copper Inorganic materials 0.000 claims abstract description 5
- 239000010949 copper Substances 0.000 claims abstract description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 5
- 239000011718 vitamin C Substances 0.000 claims abstract description 5
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 5
- 229940046009 vitamin E Drugs 0.000 claims abstract description 5
- 239000011709 vitamin E Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 229960005069 calcium Drugs 0.000 claims abstract description 3
- 235000013376 functional food Nutrition 0.000 claims abstract description 3
- 229940091250 magnesium supplement Drugs 0.000 claims abstract description 3
- 235000015097 nutrients Nutrition 0.000 claims description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 14
- 239000011707 mineral Substances 0.000 claims description 14
- 235000010755 mineral Nutrition 0.000 claims description 14
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 13
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 12
- 235000013343 vitamin Nutrition 0.000 claims description 12
- 239000011782 vitamin Substances 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 12
- 235000018102 proteins Nutrition 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000003925 fat Substances 0.000 claims description 9
- 235000019197 fats Nutrition 0.000 claims description 9
- 108010028463 kappa-casein glycomacropeptide Proteins 0.000 claims description 9
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 108010076119 Caseins Proteins 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 235000014633 carbohydrates Nutrition 0.000 claims description 7
- 239000005018 casein Substances 0.000 claims description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 7
- 235000021240 caseins Nutrition 0.000 claims description 7
- 108010001441 Phosphopeptides Proteins 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 229940108928 copper Drugs 0.000 claims description 2
- 235000018823 dietary intake Nutrition 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 description 9
- 230000035764 nutrition Effects 0.000 description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 235000006180 nutrition needs Nutrition 0.000 description 4
- 102000011632 Caseins Human genes 0.000 description 3
- 108010010256 Dietary Proteins Proteins 0.000 description 3
- 102000015781 Dietary Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000021245 dietary protein Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 235000021076 total caloric intake Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010016997 Forearm fracture Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 235000021084 monounsaturated fats Nutrition 0.000 description 1
- 235000020783 nutrient-dense food Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019527 sweetened beverage Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a nutritional composition for prevention or treatment of a bone condition, a method of production of the composition, use of the composition in the manufacture of a medicament for the prevention or treatment of a bone condition, and a method of treatment of a bone condition which comprises administering an effective amount of the composition.
- bone condition is taken to mean a condition in which the health of osseous tissue including bone or teeth is affected. It includes an ailment selected from the group which comprises osteoporosis; osteoporotic fractures and bone fractures, typically hip and forearm fractures; as well as conditions in which deficient calcium absorption, retention, resorption or calcification is implicated.
- composition is required to address the problems of preventing bone loss and recovery from bone trauma in the elderly as well as in clinical and performance settings.
- composition has now been found that can be used to provide nutrition to an elderly patient as well as performance nutrition or clinical nutrition eg. to a hospital patient.
- the invention provides a composition for prevention or treatment of a bone condition which comprises a source of protein, a source of carbohydrate, a source of fat, calcium, magnesium, zinc, vitamin D and vitamin K.
- the invention provides a method of producing a composition according to a first aspect of the invention which comprises a step of blending the required nutrients, minerals or vitamins together in the required amounts.
- the invention provides use of a composition according to a first aspect of the invention in the prevention or treatment of a bone condition.
- the invention provides use of a composition according to a first aspect of the invention in the manufacture of a functional food or medicament for the prevention or treatment of a bone condition.
- the invention provides a method of prevention or treatment of a bone condition which comprises administering an effective amount of an embodiment of a composition according to a first aspect of the invention.
- a composition according to an embodiment of the invention comprises calcium derived from milk calcium. This is a complex form of calcium which is present in milk.
- an embodiment of a composition according to the invention comprises one or more nutrients, minerals or vitamins selected from the group which consists of copper, vitamin E, vitamin C.
- the embodiment comprises at least one nutrient, mineral or vitamin selected from the group that consists of soy isoflavones, inulin, fructo-oligosaccharides, caseino- glycomacropeptide (CGMP), casein phosphopeptide or a mixture thereof. Even more preferably the embodiment comprises two or more of these nutrients. Most preferably it comprises all of these nutrients.
- inulin and fructo-oligosaccharides are provided in the form of a blend.
- the blend has a ratio of inulin:FOS of about 20 to about 45 : about 80 to about 55 by weight. More preferably the ratio of inulin:FOS is about 30:about 70 by weight.
- an embodiment comprises 10-110% of the recommended dietary intake for the elderly of the above nutrients, minerals or vitamins. More preferably it comprises the following amounts of nutrients, minerals or vitamins (if present) per 300 g of the composition. Preferably this is the amount of composition administered per day.
- Calcium preferably about 120 mg to about 1200 mg, more preferably about 800 mg
- Magnesium preferably about 42 mg to about 420 mg, more preferably about 210 mg
- Zinc preferably about 1.5 mg to about 15 mg , more preferably about 15 mg
- Vitamin D preferably about 1.5 ug to about 15 ug, more preferably about 10 ug
- Vitamin K preferably about 0.8 ug to about 80 ug, more preferably about 60 ug
- Copper preferably about 0.3 mg to about 3 mg, more preferably about 1.5 mg Vitamin E.
- Soy isoflavones preferably about 10 mg to about 200 mg, more preferably about 90 mg
- Inulin/Fructo-oligosaccharide (FOS) blend preferably about 4 g to about 50 g, more preferably about 6 g
- Caseinglycomacropeptide (CGMP) preferably about 1 g to about 100 g, more preferably about 5 g
- Casein phosphopeptide preferably about 0.1 g to about 10 g, more preferably about 0.5 g.
- an embodiment of a method according to the invention comprises the steps of blending the nutrients, minerals or vitamins in the required amounts and/or extruding the blended mixture. More preferably it includes spray drying the mixture.
- An advantage of the present invention is that it provides a nutritional composition that can be disolved instantaneously in water to provide a beverage or soup. It does not require cooking.
- Another advantage of the present invention is that it provides a single composition that can be adapted and administered simply in a food for the prevention or treatment of a bone condition.
- the compostion can be provided in clinical or performance nutrition settings and is particularly suitable for an elderly patient.
- Yet another advantage of the present invention is that it provides a composition beneficial for diabetics. This is due to the specific composition of macronutrients, protein, carbohydrate and fat which provides a low glycemic index.
- a nutritional composition comprises a source of protein.
- the protein source preferably provides about 5% to about 55% of the energy of the nutritional formula; for example about 20% to about 50%, preferably 26%, of the energy.
- Dietary protein is preferred as a source of protein.
- the dietary protein may be any suitable dietary protein; for example animal protein (such as milk protein, meat protein or egg protein); vegetable protein (such as soy protein, wheat protein, rice protein, and pea protein); a mixture of free amino acids; or a combination thereof. Milk proteins such as casein, whey proteins and soy proteins are particularly preferred.
- the composition also comprises a source of carbohydrates and a source of fat.
- a fat source preferably provides about 5% to about 55% of the energy of the nutritional formula; for example about 20% to about 50%, preferably 23%, of the energy.
- Lipid making up the fat source may be any suitable fat or fat mixture.
- Vegetable fat is particularly suitable; for example soy oil, palm oil, coconut oil, safflower oil, sunflower oil, com oil, canola oil, lecithins, and the like. Most preferably it is a mixture of canola and soy oils.
- Animal fat such as milk fat may also be added if desired.
- the composition comprises saturated fat which preferably comprises about 1% to about 5%, more preferably 2.5% of the total energy of the product.
- it comprises monounsaturated fat which preferably comprises about 5 % to about 15%, more preferably 9.9% of the total energy of the product.
- the composition comprises polyunsaturated fat which preferably comprises about 5% to about 15%, more preferably 10.1% ofthe total energy of the product.
- the composition comprises linoleic acid which preferably comprises about 5% to about 15%, more preferably 8.5%> of the total energy of the product.
- the composition comprises linolenic acid which preferably comprises about 0.5% to about 5%, more preferably 1.6% ofthe total energy ofthe product.
- the ratio of linoleic acid to linolenic acid is about 3 to about 8, more preferably about 5.3.
- a source of carbohydrate preferably provides about 40% to about 80%, more preferably about 51% of the energy of the nutritional composition.
- Any suitable carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin, or a mixture thereof.
- This embodiment of the composition additionally comprises about 800mg milk calcium, about 210mg magnesium, about 15mg zinc, about lOmg of vitamin D and about 60mg of vitamin K per 300g ofthe composition.
- Dietary fibre may also be added. It preferably comprises up to about 5% ofthe energy of the nutritional composition.
- the dietary fibre may be from any suitable origin, preferably fructooligosaccharide, acacia gum, or a mixture thereof.
- Isoflavone may be included. This provides the advantage of increasing bone mineral density and/or bone mineral content.
- Calcium may be included. Preferably this calcium is derived from milk or milk protein fractions.
- Additional suitable vitamins and minerals are included in the composition as described above.
- Monosodium glutamate may be added as a flavour enhancer.
- the nutritional composition is preferably used orally and could alternatively be enterally administrable; for example in the form of a powder, a liquid concentrate, or a ready-to-drink beverage. If it is desired to produce a powdered nutritional formula, the homogenized mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
- a usual food product may be enriched with an embodiment of composition.
- the amount of the composition added is preferably at least about 0.01% by weight.
- compositions Two nutritional compositions were made by blending the required constituents. Their compositions are indicated below in Table 1. The compositions are intended to be consumed in the form of two oral supplements per day based on an enriched beverage and/or milk product desert. The total daily dose ofthe composition is intended to be approximately 300g or 300ml ofthe composition. Table 1
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pediatric Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A nutritional composition is described for prevention or treatment of a bone condition. It comprises, in a broad definition, at least calcium, magnesium, zinc, vitamin D and vitamin K. For example, in an embodiment it comprises per 300 g: about 800 mg calcium, about 210 mg magnesium, about 15 mg zinc, about 10 ug vitamin D, about 60 ug vitamin K, about 1.5 mg copper, about 5 mg vitamin E, about 30 mg vitamin C, about 90 mg soy isoflavone and about 6 g inulin/FOS (30:70) blend. A method for making the composition; use of it in the manufacture of a functional food or medicament; and a method of prevention or treatment of a bone condition which comprises administering an effective amount of the composition are described.
Description
Nutritional Composition For a Bone Condition
The present invention relates to a nutritional composition for prevention or treatment of a bone condition, a method of production of the composition, use of the composition in the manufacture of a medicament for the prevention or treatment of a bone condition, and a method of treatment of a bone condition which comprises administering an effective amount of the composition.
Within the context of this specification the word "comprises" is taken to mean "includes, among other things". It is not intended to be construed as "consists of only".
The term "bone condition" is taken to mean a condition in which the health of osseous tissue including bone or teeth is affected. It includes an ailment selected from the group which comprises osteoporosis; osteoporotic fractures and bone fractures, typically hip and forearm fractures; as well as conditions in which deficient calcium absorption, retention, resorption or calcification is implicated.
Americans greater than 65 years old, at the turn of the century, accounted for 4% of the US population; currently, they account for greater than 12% of the population. However, although they only account for 12% of the US population, they account for greater than 40% of acute hospital bed days, buy greater than 30% of all prescription drugs and spend 30% of the US health budget. Furthermore, it has been estimated that in 2030, greater than 70 million Americans (1 :5) will be over the age of 65, and those over 85 are expected to experience the highest percentage increase of all age groups.
As the average age of the population increases, obtaining a better understanding of the unique aspects of aging in relation to nutritional needs and treatment is imperative. Many physiologic functions decline progressively throughout adult life and have an
impact on nutrition. For instance, a reduction in the number of functioning cells and the resultant slowing of metabolic processes results in a decrease in caloric requirements among the elderly. Also, the reduction in physical activity that generally accompanies aging further decreases energy requirements.
However, merely decreasing the total caloric intake of an elderly patient may adversely affect their required nutrition. When the total caloric intake is reduced, the remaining food intake must carefully insure a properly balanced intake of proteins, vitamins and minerals. To reduce caloric intake in the elderly, consumption of "empty" calories (i.e. fats) can be reduced and consumption of nutrient-dense foods (i.e. carbohydrates and proteins) can be increased.
While the nutritional needs of the mature adult differ from those of an adult, in health care settings, standard nutritional formulae are the primary form of elemental nutrition currently used. Naturally, standard formulae do not take into account the nutritional needs of an elderly patient. Standard products suffer from the problem that they must be supplemented with key micronutrients to compensate for common deficiencies and metabolic changes of an elderly patient. Therefore, a need exists for a nutritional composition which meets the nutritional needs of an elderly patient.
In addition to the above problems, a composition is required to address the problems of preventing bone loss and recovery from bone trauma in the elderly as well as in clinical and performance settings.
Furthermore, it is known that the effects of diet and nutritional supplements can play a role in improving the survival and quality of life. In particular, a need exists for a nutritional composition which can help to improve bone health.
The present invention addresses the problems set out above.
Remarkably, a composition has now been found that can be used to provide nutrition to an elderly patient as well as performance nutrition or clinical nutrition eg. to a hospital patient.
Accordingly, in a first aspect, the invention provides a composition for prevention or treatment of a bone condition which comprises a source of protein, a source of carbohydrate, a source of fat, calcium, magnesium, zinc, vitamin D and vitamin K.
In a second aspect the invention provides a method of producing a composition according to a first aspect of the invention which comprises a step of blending the required nutrients, minerals or vitamins together in the required amounts.
In a third aspect the invention provides use of a composition according to a first aspect of the invention in the prevention or treatment of a bone condition.
In a fourth aspect the invention provides use of a composition according to a first aspect of the invention in the manufacture of a functional food or medicament for the prevention or treatment of a bone condition.
In a fifth aspect the invention provides a method of prevention or treatment of a bone condition which comprises administering an effective amount of an embodiment of a composition according to a first aspect of the invention.
Preferably, a composition according to an embodiment of the invention comprises calcium derived from milk calcium. This is a complex form of calcium which is present in milk.
Preferably, an embodiment of a composition according to the invention comprises one or more nutrients, minerals or vitamins selected from the group which consists of copper, vitamin E, vitamin C.
More preferably it comprises at least one nutrient, mineral or vitamin selected from the group that consists of soy isoflavones, inulin, fructo-oligosaccharides, caseino- glycomacropeptide (CGMP), casein phosphopeptide or a mixture thereof. Even more preferably the embodiment comprises two or more of these nutrients. Most preferably it comprises all of these nutrients.
Preferably, inulin and fructo-oligosaccharides (FOS) are provided in the form of a blend. Preferably, the blend has a ratio of inulin:FOS of about 20 to about 45 : about 80 to about 55 by weight. More preferably the ratio of inulin:FOS is about 30:about 70 by weight.
Preferably, an embodiment comprises 10-110% of the recommended dietary intake for the elderly of the above nutrients, minerals or vitamins. More preferably it comprises the following amounts of nutrients, minerals or vitamins (if present) per 300 g of the composition. Preferably this is the amount of composition administered per day.
Calcium : preferably about 120 mg to about 1200 mg, more preferably about 800 mg Magnesium: preferably about 42 mg to about 420 mg, more preferably about 210 mg Zinc: preferably about 1.5 mg to about 15 mg , more preferably about 15 mg Vitamin D: preferably about 1.5 ug to about 15 ug, more preferably about 10 ug Vitamin K : preferably about 0.8 ug to about 80 ug, more preferably about 60 ug Copper: preferably about 0.3 mg to about 3 mg, more preferably about 1.5 mg Vitamin E. preferably about 1 IU to about 10 IU, more preferably about 5 IU Vitamin C: preferably about 6 mg to about 60 mg, more preferably about 30 mg
Soy isoflavones: preferably about 10 mg to about 200 mg, more preferably about 90 mg
Inulin/Fructo-oligosaccharide (FOS) blend: preferably about 4 g to about 50 g, more preferably about 6 g Caseinglycomacropeptide (CGMP): preferably about 1 g to about 100 g, more preferably about 5 g
Casein phosphopeptide (CPP): preferably about 0.1 g to about 10 g, more preferably about 0.5 g.
Preferably, an embodiment of a method according to the invention comprises the steps of blending the nutrients, minerals or vitamins in the required amounts and/or extruding the blended mixture. More preferably it includes spray drying the mixture.
An advantage of the present invention is that it provides a nutritional composition that can be disolved instantaneously in water to provide a beverage or soup. It does not require cooking.
Another advantage of the present invention is that it provides a single composition that can be adapted and administered simply in a food for the prevention or treatment of a bone condition. The compostion can be provided in clinical or performance nutrition settings and is particularly suitable for an elderly patient.
Yet another advantage of the present invention is that it provides a composition beneficial for diabetics. This is due to the specific composition of macronutrients, protein, carbohydrate and fat which provides a low glycemic index.
Additional features and advantages of the present invention are described in, and will be apparent from the description of the presently preferred embodiments which are set out below.
For the purposes of clarity and a concise description features are described herein as part of the same or separate embodiments, however it will be appreciated that the scope of the invention may include embodiments having combinations of all or some of the features described.
In an embodiment, a nutritional composition comprises a source of protein. The protein source preferably provides about 5% to about 55% of the energy of the nutritional formula; for example about 20% to about 50%, preferably 26%, of the energy. Dietary protein is preferred as a source of protein. The dietary protein may be any suitable dietary protein; for example animal protein (such as milk protein, meat protein or egg protein); vegetable protein (such as soy protein, wheat protein, rice protein, and pea protein); a mixture of free amino acids; or a combination thereof. Milk proteins such as casein, whey proteins and soy proteins are particularly preferred.
The composition also comprises a source of carbohydrates and a source of fat.
A fat source preferably provides about 5% to about 55% of the energy of the nutritional formula; for example about 20% to about 50%, preferably 23%, of the energy. Lipid making up the fat source may be any suitable fat or fat mixture. Vegetable fat is particularly suitable; for example soy oil, palm oil, coconut oil, safflower oil, sunflower oil, com oil, canola oil, lecithins, and the like. Most preferably it is a mixture of canola and soy oils. Animal fat such as milk fat may also be added if desired.
Preferably the composition comprises saturated fat which preferably comprises about 1% to about 5%, more preferably 2.5% of the total energy of the product. Preferably it comprises monounsaturated fat which preferably comprises about 5 % to about 15%, more preferably 9.9% of the total energy of the product. Preferably the composition
comprises polyunsaturated fat which preferably comprises about 5% to about 15%, more preferably 10.1% ofthe total energy of the product. Preferably the composition comprises linoleic acid which preferably comprises about 5% to about 15%, more preferably 8.5%> of the total energy of the product. Preferably the composition comprises linolenic acid which preferably comprises about 0.5% to about 5%, more preferably 1.6% ofthe total energy ofthe product. Preferably the ratio of linoleic acid to linolenic acid is about 3 to about 8, more preferably about 5.3.
A source of carbohydrate preferably provides about 40% to about 80%, more preferably about 51% of the energy of the nutritional composition. Any suitable carbohydrate may be used, for example sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin, or a mixture thereof.
This embodiment of the composition additionally comprises about 800mg milk calcium, about 210mg magnesium, about 15mg zinc, about lOmg of vitamin D and about 60mg of vitamin K per 300g ofthe composition.
Dietary fibre may also be added. It preferably comprises up to about 5% ofthe energy of the nutritional composition. The dietary fibre may be from any suitable origin, preferably fructooligosaccharide, acacia gum, or a mixture thereof.
Isoflavone may be included. This provides the advantage of increasing bone mineral density and/or bone mineral content. Calcium may be included. Preferably this calcium is derived from milk or milk protein fractions.
Additional suitable vitamins and minerals are included in the composition as described above.
Monosodium glutamate may be added as a flavour enhancer.
The nutritional composition is preferably used orally and could alternatively be enterally administrable; for example in the form of a powder, a liquid concentrate, or a ready-to-drink beverage. If it is desired to produce a powdered nutritional formula, the homogenized mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
Alternatively, a usual food product may be enriched with an embodiment of composition. For example, a fermented milk, a yogurt, a fresh cheese, a renneted milk, an article of confectionery, for example a sweet or sweetened beverage, a confectionery bar, breakfast cereal flakes or bars, a drink, milk powder, soy-based product, non-milk fermented product or a nutritional supplement for clinical nutrition. Then, the amount of the composition added is preferably at least about 0.01% by weight.
The following examples are given by way of illustration only and in no way should be construed as limiting the subject matter ofthe present application. Percentages and parts are by weight unless otherwise indicated.
Examples 1 and 2: Nutritional Compositions.
Two nutritional compositions were made by blending the required constituents. Their compositions are indicated below in Table 1. The compositions are intended to be consumed in the form of two oral supplements per day based on an enriched beverage and/or milk product desert. The total daily dose ofthe composition is intended to be approximately 300g or 300ml ofthe composition.
Table 1
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope ofthe present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
Claims
1. A nutritional composition for prevention or treatment of a bone condition which comprises a source of protein, a source of carbohydrate, a source of fat, calcium, magnesium, zinc, vitamin D and vitamin K.
2. A composition according to claim 1 wherein the calcium comprises calcium derived from milk calcium.
3. A composition according to claim 1 or 2 which comprises one or more nutrients, minerals or vitamins selected from the group which consists of copper, vitamin E, vitamin C.
4. A composition according to any preceding claim which comprises at least one nutrient selected from the group that consists of a soy isoflavone, inulin, fructo- oligosaccharide (FOS), caseino-glycomacropeptide (CGMP), casein phosphopeptide (CPP) or a mixture thereof.
5. A composition according to claim 4 comprising two or more nutrients selected from the group that consists of a soy isoflavone, inulin, fructo-oligosaccharide (FOS), caseino-glycomacropeptide (CGMP),casein phosphopeptide (CPP) or a mixture thereof.
6. A composition according to claim 4 or 5 comprising a soy isoflavone, inulin, fructo-oligosaccharide (FOS), caseino-glycomacropeptide (CGMP) and casein phosphopeptide (CPP).
7. A composition according to any one of claims 4 to 6 wherein inulin and fructo- oligosaccharide (FOS) are provided in the form of a blend.
8. A composition according to claim 7 wherein the blend has a ratio of inulin:FOS of about 30:about 70 by weight.
9. A composition according to any preceding claim which comprises nutrients, minerals or vitamins at about 10 to about 110% ofthe recommended dietary intake for the elderly.
10. A composition according to any preceding claim comprising the following amounts of nutrients, minerals or vitamins (if present) per 300 g of the composition.
Calcium : about 120 mg to about 1200mg, Magnesium: about 42 mg to about 420mg, Zinc: about 1.5 mg to about 15mg, Vitamin D: about 1.5 ug to about 15 ug, Vitamin K : about 0.8 ug to about 80 ug, Copper: about 0.3 mg to about 3mg, Vitamin E. about 1 mg to about 10 mg, Vitamin C: about 6 mg to about 60 mg, Soy isoflavone: about 10 mg to about 200 mg, Inulin/Fructo-oligosaccharide (FOS) blend: about 4 g to about 50 g, Caseinoglycomacropeptide (CGMP): about 1 g to about lOOg Casein phosphopeptide (CPP): about O.lg to about lOg.
11. A method of producing a composition according to any preceding claim which comprises a step of blending the required nutrients, minerals or vitamins together in the required amounts.
12. A method according to claim 11 comprising the steps of blending the nutrients in the required amounts and/or extruding the blended mixture and/or spray drying the mixture.
13. Use of a composition according to any one of claims 1 to 10 in the prevention or treatment of a bone condition.
14. Use of a composition according to any one of claims 1 to 10 in the manufacture of a functional food or medicament for the prevention or treatment of a bone condition.
15. A method of prevention or treatment of a bone condition which comprises administering an effective amount of an embodiment of a composition according to any one of claims 1 to 10.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0100273.2A GB0100273D0 (en) | 2001-01-08 | 2001-01-08 | Nutritional composition for a bone condition |
| GB0100273 | 2001-01-08 | ||
| PCT/EP2002/000296 WO2002052954A2 (en) | 2001-01-08 | 2002-01-08 | Nutritional composition for a bone condition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1351584A2 true EP1351584A2 (en) | 2003-10-15 |
Family
ID=9906309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP02702265A Withdrawn EP1351584A2 (en) | 2001-01-08 | 2002-01-08 | Nutritional composition for a bone condition |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1351584A2 (en) |
| AU (1) | AU2002235836A1 (en) |
| GB (1) | GB0100273D0 (en) |
| WO (1) | WO2002052954A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107853702A (en) * | 2017-11-03 | 2018-03-30 | 广州彤博士健康科技有限公司 | Compound micro-crystal powder formula and preparation method thereof |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0027761D0 (en) * | 2000-11-14 | 2000-12-27 | Nestle Sa | Nutritional composition for an immune condition |
| FR2858181B1 (en) * | 2003-07-30 | 2008-02-29 | Christian Fenioux | HYPERPROTEINED FOOD PREPARATION COMPRISING AT LEAST ONE POLYPHENOL |
| US8663679B2 (en) | 2004-04-29 | 2014-03-04 | Abbott Laboratories | Compositions for improving breast health in women |
| EP1773364B1 (en) * | 2004-07-28 | 2008-10-01 | Abbott Laboratories | Nutritional compositions and methods for treating or preventing osteoporosis |
| US7601370B2 (en) | 2004-07-28 | 2009-10-13 | Abbott Laboratories | Method for controlling body weight in estrogen-insufficient women |
| US7435431B2 (en) | 2004-07-28 | 2008-10-14 | Abbott Laboratories | Method for controlling body weight in estrogen-insufficient women |
| DE102005033630A1 (en) * | 2005-07-19 | 2007-01-25 | Humana Gmbh | Calcium-peptide component |
| DE102006052915A1 (en) * | 2006-07-28 | 2008-01-31 | Humana Gmbh | Composition, useful in pharmaceutical products to treat diarrhea and as dietary products to promote intestinal health, comprises polyphenol and milk-peptide |
| DE102006052560B4 (en) * | 2006-11-06 | 2010-01-21 | Humana Milchunion Eg | Anti-diabetogenic calcium peptide composition |
| US20080118603A1 (en) * | 2006-11-21 | 2008-05-22 | Lada Mark W | Nutritional beverage for optimal bone health |
| WO2009040087A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Therapeutic use of peptide yglf and combination with kvlpvpq |
| WO2009072885A1 (en) * | 2007-12-05 | 2009-06-11 | N.V. Nutricia | High energy liquid enteral nutritional composition |
| NL1034964C2 (en) * | 2008-01-28 | 2009-07-30 | Friesland Brands Bv | Method and compositions for the treatment of bone disorders. |
| BRPI0914793B1 (en) * | 2008-06-19 | 2019-12-10 | Nutricia Nv | nutritional composition and use of a nutritional composition |
| BRPI0913739A2 (en) | 2008-06-19 | 2015-08-18 | Nutricia Nv | Liquid composition, method, and use of composition |
| ES2546055T3 (en) | 2009-01-23 | 2015-09-18 | Wyeth Llc | Nutritional supplements for individuals 50 years or older to improve vitality, immunity, eye and bone health |
| EP2292102A1 (en) * | 2009-09-02 | 2011-03-09 | Lipofoods, S.L. | Microcapsules containing salts for food products |
| FR2963725B1 (en) * | 2010-08-16 | 2013-01-18 | Holymark | FOOD COMPOSITION FOR PREVENTING AND LIMITING MUSCLE MASS LOSS, LOSS OF BONE MINERAL DENSITY AND COGNITIVE DECLINE, PARTICULARLY IN ELDERLY PERSONS 50 YEARS OF AGE OR OVER |
| CN104472708A (en) * | 2014-11-26 | 2015-04-01 | 东北农业大学 | Milk powder capable of preventing and treating woman climacteric syndrome diseases and preparation method of milk powder |
| CN115399473A (en) * | 2021-05-27 | 2022-11-29 | 深圳市回春堂健康管理服务有限公司 | Yak marrow high-calcium protein powder composition for increasing bone density and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589468A (en) * | 1995-01-13 | 1996-12-31 | Clintec Nutrition Co. | Method for providing nutrition to elderly patients |
| US5827526A (en) * | 1995-07-11 | 1998-10-27 | Abbott Laboratories | Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans |
| US5985339A (en) * | 1996-11-22 | 1999-11-16 | Kamarei; A. Reza | Refrigeration-shelf-stable ready-to-drink complete nutritional compositions and products |
| DE69812074T2 (en) * | 1997-11-24 | 2003-12-24 | Bristol Myers Squibb Co | ENRICHED CONFECTIONERY DELIVERY SYSTEMS AND METHOD FOR THEIR PRODUCTION |
| GB9808579D0 (en) * | 1998-04-22 | 1998-06-24 | Novartis Nutrition Ag | Improvements in or relating to organic compounds |
-
2001
- 2001-01-08 GB GBGB0100273.2A patent/GB0100273D0/en not_active Ceased
-
2002
- 2002-01-08 WO PCT/EP2002/000296 patent/WO2002052954A2/en not_active Application Discontinuation
- 2002-01-08 EP EP02702265A patent/EP1351584A2/en not_active Withdrawn
- 2002-01-08 AU AU2002235836A patent/AU2002235836A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO02052954A2 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107853702A (en) * | 2017-11-03 | 2018-03-30 | 广州彤博士健康科技有限公司 | Compound micro-crystal powder formula and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002052954A2 (en) | 2002-07-11 |
| GB0100273D0 (en) | 2001-02-14 |
| WO2002052954A3 (en) | 2002-10-31 |
| AU2002235836A1 (en) | 2002-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6929793B2 (en) | Nutritional composition for treating an immune condition | |
| EP1351584A2 (en) | Nutritional composition for a bone condition | |
| AU2002221860A1 (en) | Nutritional composition for an immune condition | |
| CN102687750B (en) | Weight losing and meal replacement protein type solid beverage | |
| CN103054046B (en) | High energy liquid enteral nutritional composition | |
| RU2385647C2 (en) | Nutrition for patients suffering from obesity | |
| CN106473153A (en) | Full nutrition formula food and preparation method thereof | |
| EP1401293A1 (en) | Calorically dense liquid oral supplement | |
| NO333819B1 (en) | Infant or infant nutrition composition comprising sialic acid and method of preparation | |
| WO2009072869A1 (en) | High energy liquid enteral nutritional composition | |
| FI107014B (en) | herbal remedies | |
| KR20100016068A (en) | Liquid nutritional composition containing sodium at high concentration and method of producing the same | |
| US20030091613A1 (en) | Gelled nutritional composition and process | |
| KR20060024766A (en) | Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood | |
| US20240225072A1 (en) | Infant formula for feeding infants receiving infant formula and human breast milk | |
| AU2022287240A1 (en) | Infant formula for feeding infants receiving infant formula and human breast milk | |
| KR20160058475A (en) | Composition for Ice Cakes and Manufacturing Method Thereof | |
| JP2024043948A (en) | Composition for reducing intestinal ammonia concentration | |
| Lloyd | US whey products and child nutrition | |
| WO2014157717A1 (en) | Semi-solid highly nutritious food | |
| WO2019223819A1 (en) | Nutritional composition | |
| AU2002312973A1 (en) | Calorically dense liquid oral supplement | |
| JP2007077070A (en) | Anti-obesity agent or obesity improving agent for the critical age |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
| 17P | Request for examination filed |
Effective date: 20030726 |
|
| D17P | Request for examination filed (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20030809 |